Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat + bortezomib + dexamethasone for relapsed or refractory multiple myeloma
ISRCTN08577602Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Mar 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorinostat, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by University of Leeds. Primary endpoint: Proportion achieving at least partial response within 8 cycles. Started Mar 2012; status: completed.
02
Drugs
vorinostatbortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ISRCTN08577602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN08577602.